Medicines use before and after comprehensive medicines review among residents of long-term care facilities: a retrospective cohort study.
Australia
Drug utilization
Homes for the aged
Long-term care
Medication review
Medication therapy management
Nursing homes
Pharmacists
Residential aged care
Residential facilities
Journal
BMC geriatrics
ISSN: 1471-2318
Titre abrégé: BMC Geriatr
Pays: England
ID NLM: 100968548
Informations de publication
Date de publication:
08 06 2022
08 06 2022
Historique:
received:
20
10
2021
accepted:
25
05
2022
entrez:
8
6
2022
pubmed:
9
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
Residential Medication Management Review (RMMR) is a subsidized comprehensive medicines review program for individuals in Australian residential aged care facilities (RACFs). This study examined weekly trends in medicines use in the four months before and after an RMMR and among a comparison group of residents who did not receive an RMMR. This retrospective cohort study included individuals aged 65 to 105 years who first entered permanent care between 1/1/2012 and 31/12/2016 in South Australia, Victoria, or New South Wales, and were taking at least one medicine. Individuals with an RMMR within 12 months of RACF entry were classified into one of three groups: (i) RMMR within 0 to 3 months, (ii) 3 to 6 months, or (iii) within 6 to 12 months of RACF entry. Individuals without RMMRs were included in the comparison group. Weekly trends in the number of defined daily doses per 1000 days were determined in the four months before and after the RMMR (or assigned index date in the comparison group) for 14 medicine classes. 113909 individuals from 1979 RACFs were included, of whom 55021 received an RMMR. Across all three periods examined, decreased use of statins and proton pump inhibitors was observed post-RMMR in comparison to those without RMMRs. Decreases in calcium channel blockers, benzodiazepines/zopiclone, and antidepressants were observed following RMMR provision in the 3-6 and 6-12 months after RACF entry. Negligible changes in antipsychotic use were also observed following an RMMR in the 6-12 months after RACF entry by comparison to those without RMMRs. No changes in use of opioids, ACE inhibitors/sartans, beta blockers, loop diuretics, oral anticoagulants, or medicines for osteoporosis, diabetes or the cognitive symptoms of dementia were observed post-RMMR. For six of the 14 medicine classes investigated, modest changes in weekly trends in use were observed after the provision of an RMMR in the 6-12 months after RACF entry compared to those without RMMRs. Findings suggest that activities such as medicines reconciliation may be prioritized when an RMMR is provided on RACF entry, with deprescribing more likely after an RMMR the longer a resident has been in the RACF.
Sections du résumé
BACKGROUND
Residential Medication Management Review (RMMR) is a subsidized comprehensive medicines review program for individuals in Australian residential aged care facilities (RACFs). This study examined weekly trends in medicines use in the four months before and after an RMMR and among a comparison group of residents who did not receive an RMMR.
METHODS
This retrospective cohort study included individuals aged 65 to 105 years who first entered permanent care between 1/1/2012 and 31/12/2016 in South Australia, Victoria, or New South Wales, and were taking at least one medicine. Individuals with an RMMR within 12 months of RACF entry were classified into one of three groups: (i) RMMR within 0 to 3 months, (ii) 3 to 6 months, or (iii) within 6 to 12 months of RACF entry. Individuals without RMMRs were included in the comparison group. Weekly trends in the number of defined daily doses per 1000 days were determined in the four months before and after the RMMR (or assigned index date in the comparison group) for 14 medicine classes.
RESULTS
113909 individuals from 1979 RACFs were included, of whom 55021 received an RMMR. Across all three periods examined, decreased use of statins and proton pump inhibitors was observed post-RMMR in comparison to those without RMMRs. Decreases in calcium channel blockers, benzodiazepines/zopiclone, and antidepressants were observed following RMMR provision in the 3-6 and 6-12 months after RACF entry. Negligible changes in antipsychotic use were also observed following an RMMR in the 6-12 months after RACF entry by comparison to those without RMMRs. No changes in use of opioids, ACE inhibitors/sartans, beta blockers, loop diuretics, oral anticoagulants, or medicines for osteoporosis, diabetes or the cognitive symptoms of dementia were observed post-RMMR.
CONCLUSIONS
For six of the 14 medicine classes investigated, modest changes in weekly trends in use were observed after the provision of an RMMR in the 6-12 months after RACF entry compared to those without RMMRs. Findings suggest that activities such as medicines reconciliation may be prioritized when an RMMR is provided on RACF entry, with deprescribing more likely after an RMMR the longer a resident has been in the RACF.
Identifiants
pubmed: 35676644
doi: 10.1186/s12877-022-03187-0
pii: 10.1186/s12877-022-03187-0
pmc: PMC9178815
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
493Informations de copyright
© 2022. The Author(s).
Références
Res Social Adm Pharm. 2020 Sep;16(9):1220-1227
pubmed: 31843360
Am J Geriatr Pharmacother. 2004 Dec;2(4):257-64
pubmed: 15903284
J Am Med Dir Assoc. 2021 Jan;22(1):43-49
pubmed: 32669236
Drugs Real World Outcomes. 2017 Dec;4(4):235-245
pubmed: 29110295
Australas J Ageing. 2019 Sep;38 Suppl 2:9-25
pubmed: 31496065
J Clin Epidemiol. 2015 Aug;68(8):950-6
pubmed: 25890805
Public Health Res Pract. 2021 Sep 8;31(3):
pubmed: 34494072
Drugs Aging. 2016 Mar;33(3):199-204
pubmed: 26961696
Sr Care Pharm. 2020 Oct 1;35(10):419-433
pubmed: 32972492
Drugs Aging. 2009;26(8):677-86
pubmed: 19685933
Age Ageing. 2021 Feb 26;50(2):465-471
pubmed: 32997135
Clin Infect Dis. 2021 Jun 15;72(12):2167-2174
pubmed: 32460321
Pharmacoepidemiol Drug Saf. 2021 Nov;30(11):1560-1565
pubmed: 34382278
Cochrane Database Syst Rev. 2016 Feb 12;2:CD009095
pubmed: 26866421
Br J Clin Pharmacol. 2001 Mar;51(3):257-65
pubmed: 11298072
Drugs Aging. 2021 Jul;38(7):611-623
pubmed: 33880747
Int J Environ Res Public Health. 2021 Sep 20;18(18):
pubmed: 34574821
Aust Prescr. 2020 Aug;43(4):114-120
pubmed: 32921886
Med J Aust. 2021 Aug 2;215(3):130-136
pubmed: 34198357
Med J Aust. 2021 May;214(9):432-433
pubmed: 33410175
Aust J Gen Pract. 2021 Mar;50(3):171-174
pubmed: 33634288
Trials. 2021 Jun 11;22(1):390
pubmed: 34116708
Pharmacoepidemiol Drug Saf. 2017 May;26(5):587-591
pubmed: 28101968
J Am Geriatr Soc. 2019 Apr;67(4):644-646
pubmed: 30693954
J Am Med Dir Assoc. 2021 Dec;22(12):2540-2546.e2
pubmed: 34364847
Int J Epidemiol. 2018 Dec 1;47(6):2082-2093
pubmed: 29982445
J Am Med Dir Assoc. 2013 Nov;14(11):809-16
pubmed: 24176598
J Am Med Dir Assoc. 2020 Dec;21(12):1951-1957
pubmed: 32586719
J Am Med Dir Assoc. 2016 Sep 1;17(9):862.e1-9
pubmed: 27473899
Med J Aust. 2020 Apr;212(7):309-313
pubmed: 32045014
BMJ Open. 2018 Apr 13;8(4):e021122
pubmed: 29654048
BMJ Open. 2016 Mar 10;6(3):e009781
pubmed: 26966056
Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):803-9
pubmed: 23703741
Curr Med Res Opin. 2016;32(1):123-31
pubmed: 26455537
Age Ageing. 2020 Aug 24;49(5):814-820
pubmed: 32147721
J Am Med Dir Assoc. 2021 Jan;22(1):148-155.e1
pubmed: 33288466
Intern Med J. 2021 May;51(5):712-724
pubmed: 32359019
J Am Med Dir Assoc. 2017 Jan;18(1):87.e1-87.e14
pubmed: 27890352